Ipsen SA
http://www.ipsen.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ipsen SA
ADC Competition Heats Up In China But Caution, Pressure Also Mount
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
Driving Menarini's Future With Decisive Steps
Two years into her tenure as the head of Menarini, Elcin Barker Ergun has already inked two major cancer deals with the acquisition of Stemline and a key licensing pact with Radius Health. The future for the Italian group is bright, she explained to Scrip in an exclusive interview.
Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC
Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.
Analysts Impressed By Amryt As EB Drug Action Date Approaches
Amryt has set out its future plans to the investment community with much depending on the successful relaunch of its just-acquired acromegaly drug Mycapssa and a potential FDA approval for its epidermolysis bullosa gel Filsuvez.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Clementia Pharmaceuticals, Inc.
- Ipsen Bioscience, Inc.
- Sterix
- Tercica, Inc.
- Syntaxin Ltd.
- OctreoPharm Sciences GmbH
- Octagen Corporation